One Capital Management LLC Has $3.54 Million Position in Pfizer Inc. (NYSE:PFE)

One Capital Management LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 13.0% during the second quarter, HoldingsChannel reports. The institutional investor owned 81,799 shares of the biopharmaceutical company’s stock after selling 12,221 shares during the period. One Capital Management LLC’s holdings in Pfizer were worth $3,544,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Windward Capital Management Co. CA raised its position in shares of Pfizer by 1.1% during the 4th quarter. Windward Capital Management Co. CA now owns 571,114 shares of the biopharmaceutical company’s stock worth $24,929,000 after purchasing an additional 6,305 shares during the last quarter. Steward Partners Investment Advisory LLC raised its position in shares of Pfizer by 6.3% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 361,575 shares of the biopharmaceutical company’s stock worth $15,782,000 after purchasing an additional 21,393 shares during the last quarter. Investment Partners LTD. raised its position in shares of Pfizer by 1.7% during the 4th quarter. Investment Partners LTD. now owns 33,228 shares of the biopharmaceutical company’s stock worth $1,450,000 after purchasing an additional 540 shares during the last quarter. BKD Wealth Advisors LLC raised its position in shares of Pfizer by 2.5% during the 4th quarter. BKD Wealth Advisors LLC now owns 104,315 shares of the biopharmaceutical company’s stock worth $4,553,000 after purchasing an additional 2,561 shares during the last quarter. Finally, Intl Fcstone Inc. raised its position in shares of Pfizer by 21.2% during the 4th quarter. Intl Fcstone Inc. now owns 8,812 shares of the biopharmaceutical company’s stock worth $385,000 after purchasing an additional 1,540 shares during the last quarter. Hedge funds and other institutional investors own 71.82% of the company’s stock.

Shares of Pfizer stock traded down $0.65 during mid-day trading on Thursday, hitting $38.19. The stock had a trading volume of 1,981,427 shares, compared to its average volume of 19,805,980. The firm’s 50-day simple moving average is $43.04. Pfizer Inc. has a 12-month low of $38.14 and a 12-month high of $46.47. The company has a current ratio of 1.54, a quick ratio of 1.27 and a debt-to-equity ratio of 0.60. The company has a market cap of $230.46 billion, a price-to-earnings ratio of 12.78, a P/E/G ratio of 2.42 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 27.57%. The business had revenue of $13.26 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the prior year, the company posted $0.77 EPS. The business’s revenue for the quarter was down 1.5% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 2.82 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be paid a $0.36 dividend. The ex-dividend date of this dividend is Thursday, August 1st. This represents a $1.44 annualized dividend and a dividend yield of 3.77%. Pfizer’s dividend payout ratio (DPR) is 48.00%.

In other news, insider Alexander R. Mackenzie sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total value of $1,320,000.00. Following the transaction, the insider now directly owns 80,094 shares in the company, valued at approximately $3,524,136. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Pfizer Inc acquired 50,000 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was bought at an average price of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

Several analysts recently issued reports on PFE shares. Credit Suisse Group started coverage on shares of Pfizer in a research note on Monday, July 15th. They set a “hold” rating and a $47.00 price objective for the company. JPMorgan Chase & Co. set a $46.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Monday. Barclays reaffirmed a “hold” rating and set a $41.00 price objective on shares of Pfizer in a research note on Thursday, May 9th. Morgan Stanley cut shares of Pfizer from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $48.00 to $40.00 in a research note on Tuesday. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $49.00 price objective on shares of Pfizer in a research note on Monday, June 17th. Fifteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and an average price target of $46.44.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: Do closed-end mutual funds pay dividends?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.